Fulgent Genetics, Inc. (FLGT)

US — Healthcare Sector
Peers: IDXX  TWST  GH  DMTKQ  APPN  FVRR  KNSL  MGNI  LMND 

Automate Your Wheel Strategy on FLGT

With Tiblio's Option Bot, you can configure your own wheel strategy including FLGT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol FLGT
  • Rev/Share 9.8347
  • Book/Share 36.0546
  • PB 0.6241
  • Debt/Equity 0.0066
  • CurrentRatio 6.0101
  • ROIC -0.056

 

  • MktCap 691764394.0
  • FreeCF/Share -1.9445
  • PFCF -11.5386
  • PE -13.6566
  • Debt/Assets 0.0062
  • DivYield 0
  • ROE -0.0452

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade FLGT UBS Neutral Buy -- $30 Aug. 5, 2025

News

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
FLGT
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9 million, or ($0.19) per share Non-GAAP income.

Read More
image for news Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

About Fulgent Genetics, Inc. (FLGT)

  • IPO Date 2016-09-29
  • Website https://www.fulgentgenetics.com
  • Industry Medical - Diagnostics & Research
  • CEO Ming Hsieh
  • Employees 1313
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.